Tirzepatide (Mounjaro) is the newest dual GIP/GLP-1 agonist — more effective on weight and HbA1c than older options for many patients. Dr. Sanjay Sachdev offers candidacy assessment and supervised use from his South Delhi clinic.
Both work; Mounjaro shows higher weight loss in trials but is also newer and more expensive. The choice is patient-specific.
Standard titration, anti-nausea strategies, and a clear plan for the first 8 weeks.
Not just weight — waist, blood pressure, lipid profile, HbA1c, liver enzymes, and muscle mass.